Month archive: October, 2021

Breakthrough: Merck will share intellectual property and know-how for Covid-19 pill

Today US pharmaceutical company Merck & Co (trade name MSD) announced that it will share its intellectual property and know-how with the Medicines Patent Pool (MPP) for the production of its Covid-19 pill. This is a major breakthrough in the quest for access to medical products against Covid-19. If the authorities approve this product, the MPP can grant sublicenses to other pharmaceutical companies so they too can produce the antiviral treatment. This will give 105 low- and middle-income countries accelerated access to this drug.

Continue reading

ACT-A: put words into action to combat Covid-19

ACT-A, the global collaboration to respond to the Covid-19 pandemic, can and must do more to effectively combat this international health crisis. It must use its leverage to significantly improve equitable access to vaccines, therapeutics and diagnostics, and establish adequate funding of health systems in order to implement these commodities. Wemos fully supports the urgent recommendations on these matters of the Platform for Civil Society and Community Representatives to ACT-A.

Continue reading

Dutch government can make important contribution to global fight against corona crisis

This autumn, the Dutch government can make an important contribution to combating the global corona crisis. Three international summits are on the agenda at which the Netherlands can express its support for the temporary lifting of intellectual property rights for medical products against Covid-19, including vaccines. In a joint letter, civil society organisations Health Action International (HAI), Wemos, Oxfam Novib and Cordaid call on the cabinet to show political decisiveness.

Continue reading